| Identification | More | [Name]
2-Chloromethyl-4-methoxy-3,5-dimethylpyridine hydrochloride | [CAS]
86604-75-3 | [Synonyms]
2-CHLOROMETHYL-3,5-DIMETHYL-4-METHOXYPYRIDINE HCL
2-CHLOROMETHYL-3,5-DIMETHYL-4-METHOXYPYRIDINE HYDROCHLORIDE
2-CHLOROMETHYL-4-METHOXY-3,5-DIMETHYL PYRIDINE HCL
2-(CHLOROMETHYL)-4-METHOXY-3,5-DIMETHYLPYRIDINE HYDROCHLORIDE
2-(CHLOROMETHYL)-4-METHOXY-3,5-LUTIDINE HCL
2-CHLOROMETHYL-4-METHOXY-3,5-LUTIDINE HYDROCHLORIDE
CMDM
Omeprazole intermediate
2-(chloromethyl)-4-methoxy-3,5-dimethyl-pyridine dyhydrochloride
2-(CHLOROMETHYL)-4-METHOXY-3,5-DIMETHYL-PYRIDINEHYDROCHLORIDE(INTERMEDIATEOFOMEPRAXOLE)
2-(CHLOROMETHYL)-4-METHOXY-3,5-DIMETHYL-PYRIDINE HDYROCHLORIDE
2-CHLOROMETHYL-4-METHOXY-3,5-DIMETHYLPYRIDINE HCLOMEPRAZOLE | [EINECS(EC#)]
-0 | [Molecular Formula]
C9H13Cl2NO | [MDL Number]
MFCD00277472 | [Molecular Weight]
222.11 | [MOL File]
86604-75-3.mol |
| Chemical Properties | Back Directory | [Melting point ]
128-131 °C(lit.)
| [storage temp. ]
Inert atmosphere,Room Temperature | [solubility ]
Chloroform (Slightly), Methanol (Sparingly) | [form ]
Solid | [color ]
White to Off-White | [Water Solubility ]
Soluble in water. | [InChI]
InChI=1S/C9H12ClNO.ClH/c1-6-5-11-8(4-10)7(2)9(6)12-3;/h5H,4H2,1-3H3;1H | [InChIKey]
LCJDHJOUOJSJGS-UHFFFAOYSA-N | [SMILES]
C1(CCl)=NC=C(C)C(OC)=C1C.[H]Cl | [CAS DataBase Reference]
86604-75-3(CAS DataBase Reference) |
| Safety Data | Back Directory | [Symbol(GHS) ]
GHS07 | [Signal word ]
Warning | [Hazard statements ]
H315-H317-H319-H335-H413 | [Precautionary statements ]
P261-P264-P273-P280-P302+P352-P305+P351+P338 | [Risk Statements ]
R34:Causes burns. | [Safety Statements ]
S26:In case of contact with eyes, rinse immediately with plenty of water and seek medical advice .
S36/37/39:Wear suitable protective clothing, gloves and eye/face protection .
S45:In case of accident or if you feel unwell, seek medical advice immediately (show label where possible) . | [RIDADR ]
3261 | [WGK Germany ]
3
| [HazardClass ]
8 | [PackingGroup ]
II | [HS Code ]
29333990 | [Storage Class]
11 - Combustible Solids | [Hazard Classifications]
Aquatic Chronic 4
Eye Irrit. 2
Skin Irrit. 2
Skin Sens. 1
STOT SE 3 |
| Raw materials And Preparation Products | Back Directory | [Raw materials]
2,3,5-Collidine-->4-CHLORO-2,3,5-TRIMETHYLPYRIDINE-1-OXIDE-->2-(Chloromethyl)-3,5-dimethyl-4-methoxypyridine-->4-Methoxy-3,5-diMethylpicolinonitrile-->2-(ACETOXYMETHYL)-4-METHOXY-3,5-DIMETHYLPYRIDINE-->4-Methoxy-2,3,5-trimethylpyride-N-oxide-->2,3,5-Trimethylpyridine-1-Oxide-->4-NITRO-2,3,5-TRIMETHYLPYRIDINE-N-OXIDE-->3,5-DIMETHYL-4-METHOXY-2-PYRIDINE-->3,5-Dimethyl-4-methoxy-2-pyridinemethanol | [Preparation Products]
2-ChloroMethyl-4-Methoxy-3,5-diMethylpyridine 1-Oxide-->BIIB-021-->(4-methoxy-3,5-dimethylpyridin-2-yl)methanamine-->Ufiprazole |
| Hazard Information | Back Directory | [Chemical Properties]
White Solid | [Uses]
Intermediate in the production of the antiulcer agent Omeprazole | [Synthesis]
The general procedure for the synthesis of 2-chloromethyl-3,5-dimethyl-4-methoxypyridine hydrochloride from 4-methoxy-3,5-dimethyl-2-hydroxymethylpyridine was as follows: to a solution of 4-methoxy-3,5-dimethyl-2-hydroxymethylpyridine (25.1 g, 0.15 mol) in dichloromethane (400 mL) was added slowly and dropwise thionyl chloride (18.8 g, 0.158 mol) in dichloromethane (100 mL). 0.158 mol) to a solution of thionyl chloride (18.8 g, 0.158 mol) in dichloromethane (100 mL). The reaction was carried out at room temperature and under argon protection, and the titration process lasted for 30 minutes. After the dropwise addition, the reaction was continued with stirring at room temperature for 30 minutes. Upon completion of the reaction, the solvent was removed by distillation under reduced pressure. The solid residue obtained was suspended in hexane (200 mL) and the solid was collected by filtration. The solid was washed with hexane (50 mL) and subsequently dried in air to afford 2-chloromethyl-3,5-dimethyl-4-methoxypyridine hydrochloride 33.3 g (100% yield) as a white solid. | [References]
[1] Patent: WO2004/9583, 2004, A2. Location in patent: Page 156
[2] Patent: US2005/38076, 2005, A1. Location in patent: Page/Page column 6
[3] Patent: CN107011252, 2017, A. Location in patent: Paragraph 0063; 0064; 0066; 0068; 0072; 0074
[4] Journal of Medicinal Chemistry, 1998, vol. 41, # 11, p. 1777 - 1788
[5] Patent: US5292886, 1994, A |
|
|